Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | Emerging options for patients with DLBCL who relapse after CAR-T therapy

Emmanuel Bachy • 11 Jun 2022
EHA 2022
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies CAR-T

Emmanuel Bachy, MD, PhD, Lyon Sud Hospital Center, Lyon, France, comments on emerging treatment options for patients with diffuse large B-cell lymphoma (DLBCL) who relapse after CAR-T therapy, mentioning bispecific antibodies and allogeneic CAR-Ts. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Emmanuel Bachy

Updated findings from a Phase I/II study of golcadomide plus rituximab in R/R DLBCL 2:14
Updated findings from a Phase I/II study of golcadomide plus rituximab in R/R DLBCL
Emmanuel Bachy • 20 Jun 2025
The Phase II VALYM study: valemetostat monotherapy in patients with R/R FL 2:30
The Phase II VALYM study: valemetostat monotherapy in patients with R/R FL
Emmanuel Bachy • 20 Jun 2025
Valemetostat monotherapy in patients with R/R LBCL: primary results of the VALYM trial 2:58
Valemetostat monotherapy in patients with R/R LBCL: primary results of the VALYM trial
Emmanuel Bachy • 9 Dec 2024
Emerging CAR-T therapies for T-cell lymphoma 1:15
Emerging CAR-T therapies for T-cell lymphoma
Emmanuel Bachy • 11 Jun 2022

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals